24.98 KWD
Roche Xofluza contains 40 mg of baloxavir marboxil, a prescription antiviral medicine used for the treatment of uncomplicated influenza. Baloxavir marboxil works by inhibiting the influenza virus cap-dependent endonuclease, an enzyme required for viral replication. The 40 mg presentation is supplied as a film-coated tablet for oral administration.
Xofluza is a prescription medicine and should be taken only according to the dose and instructions provided by a healthcare professional. Dosing is determined according to factors including body weight, age and the approved indication. Follow the prescription and package leaflet carefully.
Baloxavir marboxil is a direct-acting antiviral with clinical evidence supporting its use against influenza A and B. It inhibits the cap-dependent endonuclease protein involved in influenza virus replication. Xofluza has been evaluated in clinical studies for the treatment of uncomplicated influenza and for post-exposure prophylaxis in approved patient populations.
Each film-coated tablet contains 40 mg of baloxavir marboxil. Excipients include lactose monohydrate, croscarmellose sodium, povidone, microcrystalline cellulose, sodium stearyl fumarate, hypromellose, talc and titanium dioxide. Refer to the package leaflet for complete ingredient, allergy, contraindication and interaction information.
Provides a targeted antiviral action against influenza viruses, inhibits an important stage of viral replication and is supplied as an oral film-coated tablet. Treatment should be used only when prescribed by a healthcare professional.
40 mg Baloxavir Marboxil
Film-Coated Tablet
1 Film-Coated Tablet
Japan